Skip to Content
Authors Lamarre NS, Bjorling DE
Author Profile(s)
Journal Transl Androl Urol Volume: 4 Issue: 5 Pages: 543-54
Publish Date 2015 Oct
PubMed ID 26816853
PMC ID 4708559

Botulinum toxin A (BTA) is currently used to treat a variety of painful disorders, including painful bladder syndrome/interstitial cystitis (PBS/IC). However, BTA is not consistently effective in all patients. This may be due to the disparity of causes of pain, but this may also relate to the processes by which BTA exerts anti-nociceptive effects. This review discusses mechanisms by which BTA may inhibit pain and studies of the use of BTA in PSB/IC patients. It is doubtful that any single treatment will effectively control pain in PBS/IC patients, and it is highly probable that multiple strategies will be required, both within individual patients and across the population of PBS/IC patients. The purpose of this review is to discuss those mechanisms by which BTA acts, with the intent that alternative strategies exploiting these mechanism, or work through alternative pathways, can be identified to more effectively treat pain in PBS/IC patients in the future.

Full Text Full text available on PubMed Central Copyright © 2018 The Board of Regents of the University of Wisconsin System